Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Invion ( (AU:IVX) ) has shared an announcement.
Invion has announced that partner Hanlim Pharm, backed in part by a grant from South Korea’s Korea Drug Development Fund, will provide up to A$2 million in non-dilutive funding for preclinical and regulatory work to support an Australian first-in-human clinical trial of intravenously administered HL270 (INV043) for oesophageal cancer. The two-stage program will first test efficacy, including combination studies with immune checkpoint inhibitors in animal models by the first half of 2026, and, subject to positive results, move to non-clinical stability, toxicity and manufacturing studies and preparation of Australian regulatory filings targeting completion in the second half of 2027, positioning Invion to tap into a fast-growing global oesophageal cancer therapy market projected to reach US$36.6 billion by 2035 and potentially enhancing its standing in oncology drug development.
More about Invion
Invion Limited is an ASX-listed biotechnology company focused on developing its Photosoft photodynamic therapy platform for cancer treatment, working in partnership with South Korea’s Hanlim Pharm to progress novel oncology drug candidates into clinical development, with a particular focus on indications with high unmet medical need such as oesophageal cancer.
YTD Price Performance: -71.07%
Average Trading Volume: 101,153
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$6.94M
See more insights into IVX stock on TipRanks’ Stock Analysis page.